申请人:Ono Pharmaceutical Co., Ltd.
公开号:US07906549B2
公开(公告)日:2011-03-15
The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like.
wherein all symbols are described in the specification.
本发明涉及一个由公式(I)表示的化合物,其盐,N-氧化物形式,溶剂合物或前药,以及含有该化合物的药物。由公式(I)表示的化合物具有结合S1P受体(特别是EDG-1,EDG-6和/或EDG-8)的能力,并可用于预防和/或治疗移植排斥反应,移植物抗宿主病,自身免疫性疾病,过敏性疾病,神经退行性疾病等。其中所有符号均在说明书中描述。